Clinical Trial: A Prospective, Single-Arm Phase II Clinical Trial on the Efficacy and Safety of Sintilimab Combined with Anlotinib and Taxane-Based Chemotherapy in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma Previously Treated with Immunotherapy (China)

China, Oct. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Prospective, Single-Arm Phase II Clinical Trial on the Efficacy and Safety of Sintilimab Combined with Anlotinib and Taxane-Based Chemotherapy in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma Previously Treated with Immunotherapy'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135539

Registration Time: 2026/10/30

Type: Interventional study

Primary Sponsor: The Fifth Affiliated Hospital of Sun Yat-sen University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=292907

Published by HT Digital Content Services with permission from Health...